Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access intravenous spesolimab for generalized pustular psoriasis flare
jRCT2071210127Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment emergent adverse events. Started Feb 2022; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on jRCT2071210127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210127.